Lists of World Heritage Sites

Holland America Line Partners with The Statue of Liberty-Ellis Island Foundation in Celebration of 150th Anniversary

Retrieved on: 
Wednesday, October 19, 2022
Holland America Line, Time, CCL, Revolution, Island, National Park Service, America Line, Statue of Liberty Museum, New World, Mississauga Music Walk of Fame, NYSE, Foundation, CUK, HAL, Music, Partnership, History, Oklahoma History Center, Liberty, CEO, Recreation, Family History Center, Statue, Lists of World Heritage Sites, Travel, Nightclub, Interior design, Airline

SEATTLE, Oct. 19, 2022 /PRNewswire/ -- Holland America Line will partner with The Statue of Liberty-Ellis Island Foundation, the 501c3 non-profit organization dedicated to preserving the eponymous landmarks, to celebrate the cruise line's 150-year journey from immigrant carrier to consumer ocean liner fleet. The partnership, which kicks off October 26 as Holland America Line completes the recreation of the brand's first-ever sailing from Rotterdam to New York City, features on-board video content across Holland America's entire fleet produced by an Ellis Island researcher, as well as a curated exhibit launching in 2023 at Ellis Island detailing the brand's historical prominence in bringing 1 in 10 immigrants from Europe to the United States.

Key Points: 
  • "Our history is deeply woven within the fabric of America's story," said Gus Antorcha, president, Holland America Line.
  • "Our history is deeply woven within the fabric of America's story," said Gus Antorcha, president, Holland America Line.
  • Holland America Line began the recreation of its first voyage with a sendoff October 15 from the Netherlands.
  • For more information about Holland America Line and its 150th Anniversary, consult a travel advisor, call 1-877-SAIL HAL (877-724-5425) or visit hollandamerica.com .

Horizon Therapeutics plc to Present New Data on TEPEZZA® (teprotumumab-trbw) and Thyroid Eye Disease (TED) at the American Thyroid Association (ATA) Annual Meeting

Retrieved on: 
Thursday, October 13, 2022
Biotechnology, Pharmaceutical, Optical, General Health, Health, FDA, Clinical Trials, Other Health, Pressure, Physician, LinkedIn, Spasm, Fibroblast, Breathe Me, Disease, Medicine, Diabetes, Nausea, Fatigue, Menstrual disorder, Graves' ophthalmopathy, Science, TED, Inflammatory bowel disease, Myalgia, FACP, Patient, Diarrhea, Courage, Tachycardia, Research, Twitter, Instagram, Cell, Blood pressure, Severe cognitive impairment, Hair, Nasdaq, Red, Grit, Hyperglycemia, Autoantibody, ATA, Headache, Swelling, Pain, Incidence, IBD, European Group, Lists of World Heritage Sites, Autoimmunity, Inflammation, Health, FDA, Exophthalmos, Huber loss, American Thyroid Association, Pharmaceutical industry, Vaccine, Medical device, Medical imaging, Birth control, Facebook, Dysgeusia

Horizon Therapeutics plc (Nasdaq: HZNP) today announced new data will be presented at the 91st Annual Meeting of the American Thyroid Association ( ATA 2022 ) in Montreal, October 19-23.

Key Points: 
  • Horizon Therapeutics plc (Nasdaq: HZNP) today announced new data will be presented at the 91st Annual Meeting of the American Thyroid Association ( ATA 2022 ) in Montreal, October 19-23.
  • We look forward to bringing these important data to the forefront to help physicians better understand the condition for their patients.
  • Infusion reactions have been reported in approximately 4% of patients treated with TEPEZZA.
  • Preexisting Inflammatory Bowel Disease: TEPEZZA may cause an exacerbation of preexisting inflammatory bowel disease (IBD).

Bell wins Clean50 awards for environmental innovation and accomplishment

Retrieved on: 
Friday, October 7, 2022
ISO, Digital technology, Nanotechnology, Bell, Sherbrooke, Communication, GHG, Bell's whisky, ESG, Annual report, Lists of World Heritage Sites, Carbon, Research, Corporation, WWF, Mental health, Bell Let's Talk, Partnership, Certification, Solution, MONTRAL, BCE Inc., LN2, Environment, Corporate responsibility, Internet, BCE, Technological innovation, Renewable energy, Enrique Dussel

Clean50 has named Bell the inaugural GHG Reductions Champion for achieving meaningful greenhouse gas (GHG) emissions reductions, in addition to recognizing Bell's solar cell site initiative for its environmental innovation.

Key Points: 
  • Clean50 has named Bell the inaugural GHG Reductions Champion for achieving meaningful greenhouse gas (GHG) emissions reductions, in addition to recognizing Bell's solar cell site initiative for its environmental innovation.
  • Bell has demonstrated its environmental leadership by setting increasingly ambitious GHG reduction goals since 2017.
  • Clean 50 has named Bell the inaugural GHG Reductions Champion in recognition of our success reducing the GHG emissions intensity of our operations.
  • I'm delighted that Clean50 has named Bell its inaugural GHG Reductions Champion, and recognized our Solar Cell Sites initiative as one of the Top Projects.

New Data Reveal Molecular Drivers of Thyroid Eye Disease (TED) May Remain Activated In Patients with Low Clinical Activity Score (CAS)

Retrieved on: 
Sunday, October 2, 2022
Other Health, Health, Pharmaceutical, Optical, Clinical Trials, American Academy, Autoantibody, Health, Quality of life, Pressure, Jules Stein Eye Institute, Physician, Nasdaq, Anxiety, Research, Inflammation, Therapy, Disease, CAS, Exophthalmos, Lists of World Heritage Sites, FACP, Genome, UCLA, Pain, Grit, Science, Autoimmunity, American Academy of Ophthalmology, Veni, vidi, vici, Courage, ECM, Fibroblast, European Group, Risk, Graves' ophthalmopathy, TED, Instagram, Severe cognitive impairment, University of California, AAO, Twitter, LinkedIn, Â, Cell, Extracellular matrix, Red, RNA, University, Swelling, Pharmaceutical industry, Medical device, Vaccine, Hospital, Patient, Ophthalmology, Facebook

Though high CAS patients are often distinguished by activation of immune system pathways, which remain largely unaffected in low CAS patients, IGF-1 and its related pathways were found to be upregulated in both stages of disease.

Key Points: 
  • Though high CAS patients are often distinguished by activation of immune system pathways, which remain largely unaffected in low CAS patients, IGF-1 and its related pathways were found to be upregulated in both stages of disease.
  • We are committed to pioneering research like this to better understand drivers of the evolution of this disease in order to better support patients living with Thyroid Eye Disease across the course of their lifetimes.
  • Whole Genome Transcriptome Comparison of Acute and Chronic Thyroid Eye Disease: Emergence of a Molecular Signature.
  • Inflammatory and non-inflammatory thyroid eye disease: comparison of disease signs, symptoms and quality of life in US patients.

Horizon Therapeutics plc Completes Enrollment for Phase 4 Trial of TEPEZZA® (teprotumumab-trbw) in Adults with Chronic/Low Clinical Activity Score (CAS) Thyroid Eye Disease (TED)

Retrieved on: 
Thursday, September 29, 2022
Other Health, Health, Pharmaceutical, Optical, Clinical Trials, Safety, Autoantibody, Diabetes, Inflammatory bowel disease, Health, Pressure, Patient, Hair, Clinical trial, Nasdaq, Research, Menstrual disorder, Inflammation, Disease, Headache, Diplopia, CAS, Exophthalmos, Lists of World Heritage Sites, COVID-19, Blood pressure, Food, Tachycardia, Diarrhea, Orbital, Hyperglycemia, Pain, Grit, Science, Adult, Autoimmunity, Medicine, Nausea, SEC, Courage, Fibroblast, European Group, FDA, Graves' ophthalmopathy, Week, Partnership, TED, Instagram, Cedars-Sinai Medical Center, Fatigue, Incidence, Huber loss, Twitter, Spasm, LinkedIn, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Cell, Red, Clinical, IBD, Myalgia, Swelling, Breathe Me, Pharmaceutical industry, Medical imaging, Vaccine, Medical device, Birth control, Dysgeusia, Facebook

Horizon Therapeutics plc (Nasdaq: HZNP) announced that it has completed enrollment of its Phase 4 clinical trial ( NCT04583735 ) evaluating TEPEZZA for the treatment of Thyroid Eye Disease (TED) in patients with a low Clinical Activity Score (CAS), also known as the TEPEZZA Chronic TED trial.

Key Points: 
  • Horizon Therapeutics plc (Nasdaq: HZNP) announced that it has completed enrollment of its Phase 4 clinical trial ( NCT04583735 ) evaluating TEPEZZA for the treatment of Thyroid Eye Disease (TED) in patients with a low Clinical Activity Score (CAS), also known as the TEPEZZA Chronic TED trial.
  • TEPEZZA was approved by the U.S. Food and Drug Administration (FDA) in January 2020 as the first and only medicine for Thyroid Eye Disease.
  • The TEPEZZA pivotal trial data showed significant improvement in some of the most debilitating symptoms of TED in people with more inflammatory disease.
  • We frequently hear people with Thyroid Eye Disease stress how the painful, potentially vision-threatening symptoms continue throughout the patient journey.

Open Doors Founder and Famed Bible Smuggler "Brother Andrew" Dies at Age 94

Retrieved on: 
Wednesday, September 28, 2022
Volkswagen, Anglo-French Wars, Iron Curtain, Open Doors, Andrew van der Bijl, Darkness, Human, Jesus, Lists of World Heritage Sites, Iron, World War II, Book, Autobiography, CEO, Leadership, Muslim world, Volkswagen Beetle, Beetle, Bible, Multimedia, Annual report, Islam, Amusement park, Hospital

SANTA ANA, Calif. , Sept. 28, 2022 /PRNewswire/ -- Anne Van der Bijl, the founder of international nonprofit Open Doors, and known around the world as "Brother Andrew," died yesterday at the age of 94 at his home in the Netherlands, according to a family spokesperson.

Key Points: 
  • Brother Andrew was the founder of Open Doors, the oldest worldwide ministry to persecuted Christians.
  • The Bible smuggling reached an apex in June 1981 when an Open Doors crew nosed a custom-built barge onto the China coastline under the cover of darkness.
  • "Our very mission is called 'Open Doors' because we believe that all doors are open, anytime and anywhere," Brother Andrew often explained.
  • Open Doors publishes theWorld Watch List, an annual report on the 50 countries where it is most difficult to live as a Christian.

Workato’s Automate World Tour Kicks Off in Tandem with Dreamforce 2022

Retrieved on: 
Thursday, September 22, 2022
Networks, Internet, Data Management, Technology, Software, Constellation, Group, Automation, Design Automation Conference, UiPath, CXO, Redpoint Ventures, City, Research, New, CIO, Salesforce, Organization, Social media, Broadcom Inc., Business, IDC, CEO, Solution, Tiger Global Management, Founder, Battery Ventures, General manager, Box, Insight Partners, Conference, Fortune 500, Lists of World Heritage Sites, Nutanix, Tourism, Management, Intuit

Workato , the leading enterprise automation platform, announced today it wrapped the first stop on the companys Automate World Tour 2022 , an in-person roadshow series bringing the power of automation to current customers and prospects.

Key Points: 
  • Workato , the leading enterprise automation platform, announced today it wrapped the first stop on the companys Automate World Tour 2022 , an in-person roadshow series bringing the power of automation to current customers and prospects.
  • I am thrilled we are taking our annual Automate Conference on the road with Workatos Automate World Tour 2022.
  • As the first stop on the Automate World Tour, Workato is currently hosting Automation Week at Dreamforce , a 3-day, in-person event.
  • To follow along and attend upcoming Automate World Tour 2022 events across the globe, visit here .

Abpro Finalizes Strategic Partnership with Celltrion for Worldwide Development and Commercialization of a Cancer Treatment Bispecific Antibody

Retrieved on: 
Wednesday, September 21, 2022
Biotechnology, Pharmaceutical, Health, Oncology, Autoimmunity, VP, Breast, Antibody, Company, Pancreatic cancer, Growth, Partnership, Patient, Lists of World Heritage Sites, Cancer, Eye, CEO, Technology, Head, ABP, Infection, Toxicity, Pharmaceutical industry, Vaccine, Celltrion

Through this global partnership, Abpro will receive payments from Celltrion of up to $1.75 Billion, including an equity investment, development and commercial milestone payments and worldwide profit sharing.

Key Points: 
  • Through this global partnership, Abpro will receive payments from Celltrion of up to $1.75 Billion, including an equity investment, development and commercial milestone payments and worldwide profit sharing.
  • Celltrion will be in charge of the development of ABP 102 following the completion of in vitro studies by Abpro and will have world-wide commercialization rights.
  • HER2+ type cancer is implicated in up to 30% of all cases in breast, gastric, pancreatic, and other forms of cancer.
  • We are confident this partnership will allow us to deliver the best possible care to patients suffering from HER2+ cancer.

U.S. Wireless Investment Hits Record High, CTIA Annual Survey Finds

Retrieved on: 
Tuesday, September 13, 2022
Wireless data center, Wireless, Lists of World Heritage Sites, CEO, FCC, Multimedia, Friends, Industry, Family, CTIA, Video game console, Mobile phone

WASHINGTON, Sept. 13, 2022 /PRNewswire/ -- The U.S. wireless industry invested nearly $35 billion to grow, improve and run their networks in 2021, according to CTIA's 2022 Annual Wireless Industry Survey. The record-high investment marked the fourth straight year of increased capital expenditure.

Key Points: 
  • Survey results again showed increases in wireless data use, cell sites and data-only devicesindicators of the ongoing shift to the 5G Economy.
  • "Wireless is America's most competitive industry, and that competition continues to spur record levels of investment to build the world's leading 5G networks," said Meredith Attwell Baker, CTIA President and CEO.
  • "Wireless competition is also continuing to benefit consumerspushing wireless prices down and bringing real competition to cable."
  • CTIA's comprehensive annual industry survey has tracked the evolution of the wireless industry since 1985.

Reltime and Triskel Capital forge strategic financial Web3 and Metaverse partnership in Latin America

Retrieved on: 
Tuesday, September 13, 2022
Income, Trust, Create, Triskelion, Partnership, Telecommunication, Hand, CEO, Technology, Solution, Friends, MEXICO, Family, FastTrack, DEX, Lists of World Heritage Sites, Swap, New World, Freedom, Airline, Cryptocurrency, Bank, Credit, Mobile phone, Financial services, Metaverse, Nordic, Web3

OSLO, Norway and MEXICO CITY, Sept. 13, 2022 /PRNewswire/ -- Reltime AS, a disruptive global Web3 and Metaverse financial technology company, and Triskel Capital Ltd. have entered into a long-term strategic partnership to change the way people and businesses in Latin America financially interact and transact.

Key Points: 
  • OSLO, Norway and MEXICO CITY, Sept. 13, 2022 /PRNewswire/ -- Reltime AS, a disruptive global Web3 and Metaverse financial technology company, and Triskel Capital Ltd. have entered into a long-term strategic partnership to change the way people and businesses in Latin America financially interact and transact.
  • "We are exhilarated to be strategically collaborating with Reltime," says Illiane Caballero, CEO and co-founder, Triskel Capital.
  • "This newly-formed partnership aims at revolutionising the way we in Latin America conduct our financial transactions.
  • Reltime offers cutting-edge, white-labelled B2B2C, Metaverse and Web3 solutions to telecommunications, financial service providers and other trusted partners from around the globe.